Trial intelligence / Profile preview

Third Dose WIBP-CorV in Elderly with Hypertension or Diabetes

NCT05104437Phase 4Unknown

Sponsor
China National Biotec Group
Start
Nov 2021
Primary completion
Nov 2022
Modality
Whole Inactivated Vaccines
Countries
1
01

Overview

A Phase 4 trial of inactivated SARS-CoV-2 vaccine (WIBP) in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Status: unknown.

02

Drugs

inactivated SARS-CoV-2 vaccine (WIBP)
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on NCT05104437.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05104437.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call